CIBC Asset Management Inc boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,315 shares of the medical research company’s stock after buying an additional 1,157 shares during the quarter. CIBC Asset Management Inc’s holdings in Agilent Technologies were worth $5,953,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CKW Financial Group grew its position in Agilent Technologies by 114.9% during the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after buying an additional 100 shares during the period. Global X Japan Co. Ltd. grew its position in Agilent Technologies by 161.1% during the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after buying an additional 116 shares during the period. Ashton Thomas Securities LLC acquired a new position in Agilent Technologies during the third quarter worth about $31,000. Fortitude Family Office LLC grew its position in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after buying an additional 95 shares during the period. Finally, Hanson & Doremus Investment Management lifted its holdings in shares of Agilent Technologies by 66.5% in the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 105 shares in the last quarter.
Insiders Place Their Bets
In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on A
Agilent Technologies Stock Performance
Shares of A opened at $137.21 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The company has a market capitalization of $39.15 billion, a price-to-earnings ratio of 31.04, a PEG ratio of 3.65 and a beta of 1.07. Agilent Technologies, Inc. has a 1 year low of $124.16 and a 1 year high of $155.35. The company’s 50 day simple moving average is $141.13 and its 200 day simple moving average is $139.30.
Agilent Technologies (NYSE:A – Get Free Report) last posted its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. Agilent Technologies’s revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.38 earnings per share. On average, sell-side analysts predict that Agilent Technologies, Inc. will post 5.56 EPS for the current year.
Agilent Technologies Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.72%. Agilent Technologies’s dividend payout ratio is currently 22.40%.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Recommended Stories
- Five stocks we like better than Agilent Technologies
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- 3 Small Caps With Big Return Potential
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- 3 Warren Buffett Stocks to Buy Now
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.